A Phase 2 Clinical Trial of the Combination of Pembrolizumab and Selective Androgen Receptor Modulator (SARM) GTX-024 in Patients With Advanced Androgen Receptor (AR) Positive Triple Negative Breast Cancer (TNBC)
Phase of Trial: Phase II
Latest Information Update: 25 May 2017
At a glance
- Drugs Enobosarm (Primary) ; Pembrolizumab (Primary)
- Indications Breast cancer
- Focus Adverse reactions; Therapeutic Use
- 03 May 2017 Status changed from not yet recruiting to recruiting.
- 04 Apr 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Jun 2018.
- 04 Apr 2017 Planned initiation date changed from 1 Jan 2017 to 1 Jun 2017.